Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 282 results for diarrhea

  1. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA461

  2. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.

    Technology appraisal guidance
    Published
    23 July 2014
    View recommendations

    Sections for TA319

  3. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1)

    This guideline covers diagnosing and managing gastro-oesophageal reflux disease in children and young people (under 18s). It aims to raise awareness of symptoms that need investigating and treating, and to reassure parents and carers that regurgitation is common in infants under 1 year.

    NICE guideline
    Last updated
    9 October 2019
    View recommendations

    Sections for NG1

  4. Apremilast for treating active psoriatic arthritis (TA433)

    Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.

    Technology appraisal guidance
    Published
    22 February 2017
    View recommendations

    Sections for TA433

  5. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

    Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    25 March 2014
    View recommendations

    Sections for TA307

  6. For women who are having medical abortion between 10 +1   and 12 +0  weeks, what is the efficacy and acceptability of expulsion at home compared with expulsion in a clinical setting?

    blood loss the rate of adverse events such as pain, vomiting and diarrhoea. It was unclear whether or not there was a difference in...

    Research recommendation
    Published
    8 November 2019

  7. Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA830

  8. Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

    Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

    Technology appraisal guidance
    Published
    18 February 2016
    View recommendations

    Sections for TA384

  9. Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.

    Technology appraisal guidance
    Published
    25 March 2015
    View recommendations

    Sections for TA335

  10. Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

    Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.

    Technology appraisal guidance
    Published
    12 July 2017
    View recommendations

    Sections for TA456

  11. Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)

    Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.

    Technology appraisal guidance
    Published
    27 July 2011
    View recommendations

    Sections for TA228

  12. Dyspepsia and gastro‑oesophageal reflux disease in adults (QS96)

    This quality standard covers investigating and managing symptoms of dyspepsia (indigestion) and gastro-oesophageal reflux disease (heartburn or reflux) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    23 July 2015
    View quality statements

    Sections for QS96

  13. SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (DG7)

    This guidance has been updated and replaced by NICE healthtech guidance 598.

    Diagnostics guidance
    Published
    28 November 2012

  14. SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (DG44)

    We have moved Diagnostics guidance 44 to become HealthTech guidance 598. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Diagnostics guidance
    Published
    17 November 2021

  15. Avalglucosidase alfa for treating Pompe disease (TA821)

    Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.

    Technology appraisal guidance
    Published
    24 August 2022
    View recommendations

    Sections for TA821